KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and safety of tegoprazan (LXI-15028) vs . esomeprazole in patients with erosive esophagitis: A multicenter, randomized, double-blind, non-inferiority phase Ⅲ trial.

Huiyun Zhu, Qian Xue, Yingxiao Song, Zhenyu Zhang, Xing Li, Shengxiang Lyu, Qiang Zhan, Fei Liu, Lungen Lu, Liang Zhong, Weixing Chen, Dong Shao, Yanbing Ding, Deliang Liu, Xiaozhong Yang, Zhiming Huang, Zhaoshen Li, Yiqi Du

Chin Med J (Engl) 138(19) 2464-2471

PMID39474720
PMCIDPMC12487912
DOI10.1097/CM9.0000000000003276
发表日期2024-10-30
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:生活质量量表图。
摘要

摘要

BACKGROUND: An evidence gap still exists regarding the efficacy and safety of tegoprazan in patients with erosive esophagitis (EE) in China. This study aimed to verify the efficacy and safety of tegoprazan vs . esomeprazole in patients with EE in China. METHODS: This study was a multicenter, randomized, double-blind, parallel, active-controlled, non-inferiority phase III trial of patients with EE randomized 1:1 to tegoprazan 50 mg/day vs . esomeprazole 40 mg/day. This study was conducted in 32 sites between October 24, 2018 and October 18, 2019. The primary endpoint was the cumulative endoscopic healing rate at week 8. The secondary endpoint included endoscopic healing rate at week 4, changes in the reflux disease questionnaire (RDQ) and gastroesophageal reflux disease health-related quality of life (GERD-HRQL) scores, and symptom improvement. RESULTS: A total of 261 patients were randomized: 132 to the tegoprazan group and 129 to the esomeprazole group. The cumulative endoscopic healing rate at 8 weeks in the tegoprazan group was non-inferior to that of the esomeprazole group (91.1% vs . 92.8%, difference: -1.7%, 95% confidence interval [CI]: -8.5%, 5.0%, P = 0.008). There were no statistically significant differences in the changes in RDQ (total, severity, and frequency) and GERD-HRQL scores between the two groups (all P >0.05). The percentages of days without symptoms, including daytime and nighttime symptoms based on patients' diaries, were similar between the two groups (all P >0.05). In the tegoprazan and esomeprazole groups, 71.5% (93/130) and 61.7% (79/128) of the participants reported adverse events (AEs), 2.3% and 0 experienced serious AEs, while 70.0% and 60.2% had treatment-emergent AEs, respectively. CONCLUSION: Tegoprazan 50 mg/day demonstrated non-inferior efficacy in healing EE, symptom improvement, and quality of life, and it has similar tolerability compared with esomeprazole 40 mg/day. TRIAL REGISTRATION: ClinicalTrials.gov , NCT03615677.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 The flowchart of the participants with EE randomized to tegoprazan vs. esomeprazole group. EE: Erosive esophagitis. * The patient was noncompliant and could not attend scheduled visits. † The patient planned to become pregnant. ‡ One patient did not want to continue participating in the study and one patient did not want to undergo endoscopy.
非 KM Figure
Figure 2Figure 2 Changes in RDQ (A) total, (B) severity, and (C) frequency and GERD-HRQL Scores (D). GERD-HRQL: Gastroesophageal reflux disease health-related quality of life; RDQ: Reflux disease questionnaire.
非 KM Figure